Keywords: novartis, femara, shows, advantage, over, tamoxifen, advanced

Novartis' Femara "shows advantage" over tamoxifen in advanced breast cancer

Article | 09 June 2003

Print This

In what is said to be the largest study ever to evaluate a hormonal therapy in advanced breast cancer, Swiss ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in